Table 3. 14q32 Translocation events in multiple myeloma.
| Translocations | Events per Training-set Population (n=268) (%) | Events per Test-set Population (n=792) (%) |
|---|---|---|
|
IGHV–MMSET t(4;14)(p16;q32) |
40 (14.9%) | 118 (14.9%) |
|
IGHC–FGFR3 t(4;14)(p16;q32)a |
27 (10.1%) | 77 (10.0%) |
|
IGHC–CCND3 t(6;14)(p21;q32) |
9 (3.4%) | 11 (1.4%) |
|
IGHC–CCND1 t(11;14)(q13;q32) |
52 (19.4%) | 157 (19.8%) |
|
IGHC–MAF t(14;16)(q32;q23) |
9 (3.4%) | 35 (4.4%) |
|
IGHC–MAFB t(14;20)(q32;q12) |
3 (1.1%) | 14 (1.8%) |
| Total | 113 (42.2%) | 335 (42.3%) |
a
Chromosomal translocation events of FGFR3 with IGH were always associated with the events of MMSET with IGH in 67% of MM patients who were defined as t(4;14); in the current study, overall t(4;14) translocation events were represented by MMSET translocations alone.